Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,617Revenue $M287Net Margin (%)-26.6Z-Score9.4
Enterprise Value $M4,304EPS $-0.6Operating Margin %-27.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-26.6Higher ROA y-yN
Price/Book21.910-y EBITDA Growth Rate %-4.9Quick Ratio2.9Cash flow > EarningsY
Price/Sales16.05-y EBITDA Growth Rate %-12.7Current Ratio3.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-16.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-33.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M124ROI % (ttm)-20.8Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 37.1471%Sold Out0
SGENJean-Marie Eveillard 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 37.1474%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 37.1469%Sold Out0
SGENJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 37.1476%Sold Out0
SGENJean-Marie Eveillard 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 37.1475%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cline Darren SSVP, Commercial 2015-03-13Sell7,500$38.65-3.91 view
HIMES VAUGHN BEVP, Proc Svcs & Tech Ops 2015-03-12Sell20,000$36.651.34 view
BAKER FELIXDirector, 10% Owner 2015-03-10Buy285,036$34.667.16 view
BAKER FELIXDirector, 10% Owner 2015-03-04Buy448,841$34.846.6 view
BAKER FELIXDirector, 10% Owner 2015-02-25Buy281,115$33.929.49 view
SIEGALL CLAY BPresident and CEO 2015-01-06Sell16,804$31.816.79 view
BAKER FELIXDirector, 10% Owner 2014-12-16Buy2,883,378$31.8616.57 view
BAKER FELIXDirector, 10% Owner 2014-12-10Buy1,247,896$33.829.82 view
FBB3 LLCDirector, 10% Owner 2014-12-09Sell0$09.82 view
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci. 2014-11-12Sell10,000$37.52-1.01 view

Press Releases about SGEN :

Quarterly/Annual Reports about SGEN:

    News about SGEN:

    Articles On GuruFocus.com
    Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
    Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    Comment for Companies Ranked by Business Predictability Jan 03 2013 
    Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
    WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
    Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 

    More From Other Websites
    Seattle Genetics' exec: Here's how to stay an independent biotech in Seattle Apr 24 2015
    Has Biotech Turned the Corner? Apr 23 2015
    Seattle Genetics (SGEN) is the 'Chart of the Day' Apr 22 2015
    Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog Apr 21 2015
    FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the... Apr 20 2015
    FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the... Apr 20 2015
    Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR)... Apr 16 2015
    Seattle Genetics Highlights Broad Presence at the American Association for Cancer Research (AACR)... Apr 16 2015
    Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2015 Financial... Apr 13 2015
    SEATTLE GENETICS INC /WA Financials Mar 06 2015
    Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
    10-K for Seattle Genetics, Inc. Mar 01 2015
    SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report Feb 27 2015
    Seattle Genetics to Present at Upcoming Investor Conferences Feb 26 2015
    Seattle Genetics to Present at Upcoming Investor Conferences Feb 25 2015
    Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Feb 19 2015
    Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Feb 18 2015
    Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
    Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
    Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced... Feb 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK